Clinical trials: Virus Disease
Chronic Hepatitis C
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
The purpose of this study is to evaluate the efficacy and safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.
- Trial name
- NCT03020082
- Testing
- Danoprevir, Ritonavir, peginterferon alfa-2a
- Volunteers
- 141 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Diphtheria, Tetanus
Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine
The purpose of this study is to evaluate the long term immunogenicity produced in children by the investigational hexavalent vaccine (DTaP-IPV-Hep B-PRP-T) given in Study A3L15 (NCT 00362336).
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01105559
- Where
- 2 sites in South Africa
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Sanofi
Obesity, HIV Infections
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period ends.
- Trial name
- NCT00267527
- Testing
- CJC 1295
- Volunteers
- 120 people
- Sponsor
- ConjuChem
Measles, Mumps
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
The primary study objectives are: To demonstrate that a 2-dose regimen of ProQuad® manufactured with recombinant Human Albumin (rHA) administered at a 3-month interval to healthy children of 11 months of age at the time of Dose 1…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00566527
- Testing
- ProQuad® manufactured with recombinant Human Albumin (rHA)
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus Type 1
A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
The purpose of this study is to evaluate the antiviral activity as measured by the change in viral load from baseline in the 14 days following initiation of treatment with 4 different dose regimens of TMC310911 co-administered…
- Trial name
- NCT00838162
- Testing
- TMC310911 75 mg twice daily, TMC310911 150 mg twice daily, TMC310911 300 mg twice daily
- Where
- 3 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen
The purpose of this study is to demonstrate that virologically controlled HIV-infected individuals can successfully switch from a standard-of-care regimen dosed twice-daily or more frequently to a simpler once-daily (QD) regimen…
- Trial name
- NCT00135369
- Testing
- stavudine extended-release, lamivudine, efavirenz
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Assessing the Safety of Dapivirine Gel and Film Formulations
This is a study to determine the safety of dapivirine gel and dapvirine film for healthy, HIV-uninfected women aged 18-45 years using the product for 7 daily doses.
- Trial name
- NCT01548560
- Testing
- Dapivirine Vaginal Film, Dapivirine Vaginal Gel
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Post Polio Syndrome, PPS
Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)
The primary objective was to assess the effect of Xepol compared to placebo on physical health and on muscle strength in subjects with post-polio syndrome.The secondary objective was to assess the effect of Xepol compared to…
- Trial name
- NCT00160082
- Testing
- Xepol
- Where
- 4 sites in Sweden
- Volunteers
- 124 people
- Sponsor
- Calliditas Therapeutics AB
Hepatitis C
Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)
This is a two-part dose-finding trial of MK-7680 in participants with Hepatitis C Virus (HCV) infection of genotype (GT)1 (Part I) and GT3 (Part 2).
- Trial name
- NCT02269059
- Testing
- MK-7680
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Dengue
Study of AT-752 in Healthy Subjects
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-752 in healthy subjects
- Trial name
- NCT04722627
- Testing
- AT-752
- Where
- Australia
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
The goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in…
- Trial name
- NCT02016924
- Testing
- ATV, DRV, Cobicistat
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 133 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1 (GT-1), treatment-naive, hepatitis C virus (HCV)…
- Trial name
- NCT01849562
- Testing
- Sovaprevir, ACH-3102, Ribavirin
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections
A Long Term Safety Study of Apricitabine in HIV-infected Patients
This study will examine the long term safety of apricitabine in HIV-1 infected patients from studies AVX-301 or AVX-302. Eligible patients are those who have either (a)completed studies AVX-301 or AVX-302; or (b)met the criteria…
- Trial name
- NCT00686270
- Testing
- apricitabine
- Sponsor
- Avexa
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00474370
- Testing
- Vicriviroc
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients
The proposed project will pilot incorporation of rapid serial measurements of IP-10 into a CDS tool for moderate and severe COVID-19 patients.
- Trial name
- NCT04389645
- Testing
- IP-10 in CDS protocol
- Where
- Israel
- Volunteers
- 52 people
- Sponsor
- MeMed Diagnostics Ltd.
Hepatitis B
A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants
This is an open-label study being done to compare two different methods of study medicine bepirovirsen is given in healthy adults.
- Trial name
- NCT07905157
- Testing
- Bepirovirsen
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Tetanus
Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.
This phase 3b study will compare the immunogenicity and reactogenicity of the dTpa-IPV vaccine to that of a DTPa-IPV vaccine when administered as a booster dose in healthy children 5-6 years of age who have received three primary…
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria, Poliomyelitis
- Trial name
- NCT00871000
- Testing
- Boostrix Polio™ 711866, Priorix Tetra TM 208136, Tetravac TM
- Where
- 8 sites in Italy
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus-1
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients
This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients.
- Trial name
- NCT00827112
- Testing
- maraviroc
- Where
- 39 sites in United States, Germany and 1 more
- Volunteers
- 129 people
- Sponsor
- ViiV Healthcare
Hepatitis B, Chronic, Hepatitis D, Chronic
A Long Term Follow-up Study of Patients From the REP 301 Protocol
The REP 301 treatment protocol involved the treatment of patients with chronic hepatitis B / hepatitis D co-infection with two agents: REP 2139-Ca and pegylated interferon (peg-IFN).
- Trial name
- NCT02876419
- Where
- Moldova
- Volunteers
- 11 people
- Sponsor
- Replicor Inc.
Covid19
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)
This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have…
- Trial name
- NCT04900428
- Testing
- COVI-DROPS
- Where
- United Kingdom
- Volunteers
- 179 people
- Sponsor
- Sorrento Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.